PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33941543-1	2021	Givosiran is a N-acetylgalactosamine (GalNAc)-conjugated RNA interference (RNAi) therapeutic that targets 5"-aminolevulinate synthase 1 (ALAS1) messenger RNA (mRNA) in the liver and is currently marketed for the treatment of acute hepatic porphyria (AHP).	N-acetylgalactosaminuronic acid	38-44	5'-aminolevulinate synthase 1	Homo sapiens	106-135	
33941543-1	2021	Givosiran is a N-acetylgalactosamine (GalNAc)-conjugated RNA interference (RNAi) therapeutic that targets 5"-aminolevulinate synthase 1 (ALAS1) messenger RNA (mRNA) in the liver and is currently marketed for the treatment of acute hepatic porphyria (AHP).	N-acetylgalactosaminuronic acid	38-44	5'-aminolevulinate synthase 1	Homo sapiens	137-142	
31792921-9	2020	The clinical performance of givosiran revealed that suppression of ALAS1 by GalNac-decorated siRNAs represents an additional approach for the treatment of patients with AIP that manifests recurrent acute neurovisceral attacks.	N-acetylgalactosaminuronic acid	76-82	5'-aminolevulinate synthase 1	Homo sapiens	67-72	
26528940-4	2015	Herein, we report the development of ALN-AS1, an investigational GalNAc-conjugated RNAi therapeutic targeting ALAS1.	N-acetylgalactosaminuronic acid	65-71	5'-aminolevulinate synthase 1	Homo sapiens	110-115